Glofitamab Combo Boosts Survival vs Rituximab in Relapsed/Refractory DLBCL

Fact checked by" Russ Conroy
News
Article

The safety profile for glofitamab plus gemcitabine and oxaliplatin in diffuse large B-cell lymphoma was consistent with known risks for individual drugs.

Efficacy data from the trial revealed that after a median follow-up of 24.7 months, glofitamab plus GemOx exhibited superior OS vs rituximab/GemOx; the median OS was not evaluable vs 13.5 months in respective groups.

Efficacy data from the trial revealed that after a median follow-up of 24.7 months, glofitamab plus GemOx exhibited superior OS vs rituximab/GemOx; the median OS was not evaluable vs 13.5 months in respective groups.

Glofitamab (Columvi) plus chemotherapy with gemcitabine and oxaliplatin (GemOx) showed enhanced progression-free survival (PFS) and overall survival (OS) outcomes vs rituximab (Rituxan) plus GemOx in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a 2-year follow-up analysis of the phase 3 STARGLO trial (NCT04408638) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Efficacy data from the trial revealed that after a median follow-up of 24.7 months, glofitamab plus GemOx exhibited superior OS vs rituximab/GemOx; the median OS was not evaluable (NE; 95% CI, 19.2-NE) vs 13.5 months (95% CI, 7.9-18.5; HR, 0.60; 95% CI, 0.42-0.85; P = .003). Additionally, the 24-month OS rate in each arm was 54.4% (95% CI, 46.8%-62.0%) vs 33.6% (95% CI, 22.9%-44.2%). The median PFS in each arm was 13.8 months (95% CI, 8.8-30.0) vs 3.6 months (95% CI, 2.5-7.1), with respective 18-month PFS rates of 46.5% (95% CI, 38.5%-54.5%) vs 23.0% (95% CI, 11.5%-34.4%).

The objective response rates (ORRs) in the glofitamab and rituximab arms were 68.3% (95% CI, 61.0%-75.0%) vs 40.7% (95% CI, 30.5%-51.5%). Furthermore, the complete response (CR) rate with glofitamab was 58.5% (95% CI, 51.0%-65.7%) vs 25.3% (95% CI, 16.8%-35.5%) with rituximab. Among responders to glofitamab, the median duration of CR was not reached (NR; 95% CI, 27.2-NE) vs 24.2 months (95% CI, 6.9-NE) for responders to rituximab. A total of 42.1% of the glofitamab arm and 17.6% of the rituximab arm had an ongoing CR at data cut-off.

Following the end of treatment, the median OS and PFS was NE in the glofitamab arm. The respective 12-month OS and PFS rates were 89.3% (95% CI, 82.3%-96.4%) and 82.4% (95% CI, 72.2%-92.5%).

“With 2-year follow-up data of the [phase 3] STARGLO trial, glofitamab/GemOx continues to show a sustained benefit in OS, PFS, and response compared to [rituximab]/GemOx,” Jeremy S. Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital and a professor of Medicine at Harvard Medical School, said in the presentation. “We saw that more than half of patients remain alive after glofitamab/GemOx, and the majority of responders were not only alive, but progression-free.”

Patients in the phase 3 trial were randomly assigned 2:1 to receive glofitamab plus GemOx (n = 183) or rituximab plus GemOx (n = 91). Those in the glofitamab arm received step-up dosing in cycle 1, then a 30 mg target dose every 31 days starting cycle 2, day 1. Patients were given 8 cycles of glofitamab with GemOx followed by 4 cycles of glofitamab as monotherapy.

In the rituximab and glofitamab arms, respectively, the median age was 69.0 years (range, 20-84) vs 68.0 years (range, 22-88), 58.2% vs 57.4% of patients were male, and 56.0% vs 47.0% were Asian. A total of 62.6% vs 62.8% had 1 prior line of therapy, 51.6% vs 57.9% were primary refractory to last treatment, and 90.9% vs 88.9% had an ECOG performance status of 0 or 1. Furthermore, 77.8% vs 66.7% had Ann Arbor stage III or IV disease, 15.6% vs 12.6% had bulky disease of 10 cm or greater, and 8.8% vs 7.7% received prior CAR T-cell therapy.

The primary end point of the trial was OS. Secondary end points included independent review committee–assessed PFS and CR rates, with a landmark analysis of patients with CRs at end of treatment performed.

Among those treated with rituximab and glofitamab, 17.0% vs 52.3% experienced serious adverse effects (AEs). Furthermore, 40.9% vs 76.7% experienced grade 3 or higher AEs, including 4.5% vs 7.0% of the respective arms experiencing grade 5 AEs. AEs leading to treatment discontinuation occurred in 12.5% and 25.6% of the rituximab and glofitamab arms.

In the glofitamab arm, the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) was 44.8% and 2.3%, with respective grade 3/4 rates of 2.3% and 0.6%. Infections of any grade occurred in 29.5% and 55.2% of the rituximab and glofitamab arms, respectively, with 9.1% and 16.9% of patients experiencing grade 3/4 infections, and 3.4% vs 3.5% experiencing grade 5 infections.

Reference

Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. J Clin Oncol. 2025;43(suppl 16):7015. doi:10.1200/JCO.2025.43.16_suppl.7015

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Related Content